

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.

Anthony Dorr¹, Charu Chopra², Tanya Coulter I³, John Dempster⁴, Magdalena Dziadzio⁴, Tariq El-Shanawany⁵, Tomaz Garcez⁶, Mark Gompels⁷, Richard Herriot⁸, Rashmi Jain⁹, Marcel Levi⁴, Lorena Lorenzo¹, Inas Makki³, Elizabeth Mapazire¹, Sai Murng¹⁰, Sadia Noorani¹¹, Sinisa Savic¹², Cathal L. Steele¹³, Christine Symons¹⁴, Michael Tarzi¹⁵, Patrick Yong¹⁶, and Sorena Kiani-Alikhan¹

¹Barts Health NHS Trust

²Royal Infirmary of Edinburgh

³Belfast Health and Social Care Trust

⁴University College Hospital

⁵University Hospital of Wales

⁶Manchester University NHS Foundation Trust

⁷North Bristol NHS Trust

⁸NHS Grampian

⁹Oxford University Hospitals NHS Foundation Trust

¹⁰Epsom and Saint Helier University Hospitals NHS Trust

¹¹Sandwell and West Birmingham Hospitals NHS Trust

¹²St James's University Hospital

¹³NHS Tayside

¹⁴University Hospitals Plymouth NHS Trust

¹⁵Royal Sussex County Hospital

¹⁶Frimley Health NHS Foundation Trust

September 12, 2022

Hosted file

Lanadelumab audit manuscript.docx available at <https://authorea.com/users/487729/articles/585566-lanadelumab-for-the-prevention-of-hereditary-angioedema-attacks-a-real-world-uk-audit>